Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

  • Details

ClinicalTrials.gov ID: NCT05306340
Diagnosis Type: Breast Cancer
USOR Number: 22018

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

  • Details

ClinicalTrials.gov ID: NCT05306340
Diagnosis Type: Breast Cancer
USOR Number: 22018

  • Practice Details

1620 W. St. Mary's Rd.
Tucson, AZ 85745
P: (520) 624-7445

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

  • Details

ClinicalTrials.gov ID: NCT05306340
Diagnosis Type: Breast Cancer
USOR Number: 22018

  • Practice Details

2070 W. Rudasill Rd., #130
Tucson, AZ 85704
P: (520) 797-4468

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

  • Details

ClinicalTrials.gov ID: NCT05306340
Diagnosis Type: Breast Cancer
USOR Number: 22018

  • Practice Details

1845 W. Orange Grove, Bldg. 2
Tucson, AZ 85704
P: (520) 624-7445

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

  • Details

ClinicalTrials.gov ID: NCT05232916
Diagnosis Type: Breast Cancer
USOR Number: 21462

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

  • Details

ClinicalTrials.gov ID: NCT05232916
Diagnosis Type: Breast Cancer
USOR Number: 21462

  • Practice Details

1620 W. St. Mary's Rd.
Tucson, AZ 85745
P: (520) 624-7445

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

  • Details

ClinicalTrials.gov ID: NCT05232916
Diagnosis Type: Breast Cancer
USOR Number: 21462

  • Practice Details

2070 W. Rudasill Rd., #130
Tucson, AZ 85704
P: (520) 797-4468

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

  • Details

ClinicalTrials.gov ID: NCT05232916
Diagnosis Type: Breast Cancer
USOR Number: 21462

  • Practice Details

1845 W. Orange Grove, Bldg. 2
Tucson, AZ 85704
P: (520) 624-7445

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

  • Details

ClinicalTrials.gov ID: NCT03872947
Diagnosis Type: Peritoneal Cancer
USOR Number: 21304

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)

  • Details

ClinicalTrials.gov ID: NCT03872947
Diagnosis Type: Peritoneal Cancer
USOR Number: 21304

  • Practice Details

2070 W. Rudasill Rd., #130
Tucson, AZ 85704
P: (520) 797-4468

More Details View Practice Page
1 2 3 25